Baker McKenzie Advises a Consortium led by SPE Capital, and included EBRD, Proparco and BIO on their Investment in Leading Ophthalmic Pharmaceutical Manufacturer
Through its Private Equity Fund III (PEF III), Baker McKenzie has provided advice to a group of investors led by SPE Capital regarding their investment in a European holding company that is the parent company of Orchidia Pharmaceutical Industries S.A.E., a prominent manufacturer of ophthalmic pharmaceuticals with operations in Egypt and throughout the Middle East and Africa.